Analysts Set Tyra Biosciences, Inc. (NASDAQ:TYRA) Target Price at $46.90

Tyra Biosciences, Inc. (NASDAQ:TYRA) has received a consensus recommendation of “Moderate Buy” from the fifteen ratings firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, twelve have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $46.90.

A number of brokerages have weighed in on TYRA. Wolfe Research initiated coverage on shares of Tyra Biosciences in a report on Tuesday, May 19th. They set a “peer perform” rating on the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $42.00 price objective on shares of Tyra Biosciences in a research report on Wednesday, August 5th. Bank of America increased their price objective on shares of Tyra Biosciences from $37.00 to $42.00 and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a report on Friday, July 17th. Finally, HC Wainwright reissued a “buy” rating and issued a $45.00 target price on shares of Tyra Biosciences in a report on Thursday, May 14th.

Tyra Biosciences Trading Up 0.5%

Shares of NASDAQ TYRA opened at $25.30 on Thursday. The company has a market capitalization of $1.51 billion, a price-to-earnings ratio of -10.54 and a beta of 0.77. Tyra Biosciences has a twelve month low of $9.96 and a twelve month high of $40.65. The business has a 50 day simple moving average of $29.83 and a 200-day simple moving average of $32.59.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.04). As a group, equities analysts predict that Tyra Biosciences will post -2.72 earnings per share for the current year.

Institutional Trading of Tyra Biosciences

Several hedge funds have recently made changes to their positions in TYRA. Hilton Head Capital Partners LLC bought a new position in Tyra Biosciences during the 1st quarter worth $30,000. Caitong International Asset Management Co. Ltd acquired a new stake in Tyra Biosciences in the fourth quarter worth $51,000. Chung Wu Investment Group LLC bought a new stake in Tyra Biosciences in the fourth quarter valued at $53,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Tyra Biosciences by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock valued at $68,000 after acquiring an additional 534 shares during the period. Finally, State of Wyoming acquired a new position in shares of Tyra Biosciences during the second quarter valued at $76,000. Institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.